Skip to main content

Table 2 Risk of re-operation due to post-surgical bleeding after breast cancer surgery according to SSRI prescription among 14,464 women#.

From: Use of selective serotonin reuptake inhibitors and risk of re-operation due to post-surgical bleeding in breast cancer patients: a Danish population-based cohort study

  Re-operation/Cohort members Risk (%) Crude RR (95%CI) Adjusted RR* (95%CI)
SSRI Prescription     
   Never 338/12872 2.6 1.0 1.0
   Ever 51/1592 3.2 1.2 (0.91, 1.7) 1.1(0.83, 1.5)
Temporality^ of SSRI prescription     
   Never 338/12872 2.6 1.0 1.0
   Current 14/201 7.0 2.7 (1.6, 4.4) 2.3 (1.4, 3.9)
   Former 37/1391 2.7 1.0 (0.72, 1.4) 0.93 (0.66, 1.3)
  1. Risk of re-operation occurring in the first fourteen days after surgery was estimated in never, ever, current and former users.
  2. Current users were defined as women with a prescription of SSRI within 30 days before initial breast cancer surgery.
  3. Former users were defined as women with a prescription of SSRI more than 30 days before initial breast cancer surgery.
  4. # Women diagnosed in Northern Denmark between 1996 and 2007 with complete prescription coverage since 1999.
  5. ^Temporality of current use of SSRI was defined as prescriptions within 30 days prior to admission for surgery.
  6. *Adjusted for age
  7. SSRI = Selective serotonin reuptake inhibitors, RR = risk ratio, CI = 95% confidence interval